You can read our earlier discussions of Taro here and here.
Taro reported their quarterly results a few weeks back. If I had to write three to five pages on their earnings results, I might tell a few stories to take up the first four pages. There just is not that much new information in Taro’s reports or much excitement surrounding the quarterly ups and downs of a generic pharma company. For...
